Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) saw a significant drop in short interest in October. As of October 15th, there was short interest totalling 21,000 shares, a drop of 27.8% from the September 30th total of 29,100 shares. Based on an average daily trading volume, of 510,200 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.7% of the shares of the company are sold short.
Tenax Therapeutics Price Performance
Shares of NASDAQ:TENX traded up $0.12 during midday trading on Monday, hitting $4.87. The stock had a trading volume of 94,870 shares, compared to its average volume of 276,528. The company’s 50-day moving average price is $3.80 and its 200-day moving average price is $3.59. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $61.20.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($1.99) by $0.16. On average, equities research analysts predict that Tenax Therapeutics will post -6.62 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on TENX
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Tenax Therapeutics
- What Investors Need to Know About Upcoming IPOs
- Inflation Risk Rising, Key Trades Investors Are Making Now
- What is the NASDAQ Stock Exchange?
- 3 Oil Stocks to Watch Before Earnings Come Out
- What is the Shanghai Stock Exchange Composite Index?
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.